» Articles » PMID: 37550352

Long-term Surgical Results of Trabeculectomy for Secondary Glaucoma in Val30Met Hereditary Transthyretin Amyloidosis

Overview
Journal Sci Rep
Specialty Science
Date 2023 Aug 7
PMID 37550352
Authors
Affiliations
Soon will be listed here.
Abstract

This study reports the long-term results of trabeculectomy (LEC) for secondary glaucoma in hereditary transthyretin (ATTRv) amyloidosis patients and its correlation with prior vitrectomy. A retrospective case series was conducted involving 31 consecutive eyes of 20 ATTRv amyloidosis patients who underwent LEC between 2007 and 2020. The mean follow-up period was 73.2 ± 37.0 months (range: 20-181 months). Postoperative intraocular pressures (IOPs) were evaluated based on the following criteria: (a) IOP between 6 and 21 mmHg without additional glaucoma surgeries, except for laser suture lysis, (b) IOP between 6 and 15 mmHg without additional glaucoma surgeries, except for laser suture lysis, and (c) IOP between 6 and 21 mmHg without additional glaucoma surgeries, except for needling and laser suture lysis. Kaplan-Meier analysis revealed survival rates after LEC of 0.52 at 36 months, 0.42 at 60 months, and 0.25 at 84 months under criterion (a); 0.49 at 36 months, 0.27 at 60 months, and 0.11 at 84 months under criterion (b); and 0.76 at 36 months, 0.71 at 60 months, and 0.65 at 84 months under criterion (c). Eyes with a history of small gauge transconjunctival vitrectomy (SGTV) exhibited a tendency towards lower survival rates, although no statistically significant difference was observed (log-rank test; p = 0.193 under criterion (a) and p = 0.0553 under criterion (b)). Our findings suggest that LEC and additional needling procedures can provide some control over IOP; however, the overall postoperative outcomes of LEC for ATTRv amyloidosis remain unsatisfactory, even in the era of SGTV with reduced conjunctival scarring.

Citing Articles

Fighting Bleb Fibrosis After Glaucoma Surgery: Updated Focus on Key Players and Novel Targets for Therapy.

Sacchi M, Tomaselli D, Ruggeri M, Aiello F, Sabella P, Dore S Int J Mol Sci. 2025; 26(5).

PMID: 40076946 PMC: 11900438. DOI: 10.3390/ijms26052327.


Smart Contact Lenses-A Step towards Non-Invasive Continuous Eye Health Monitoring.

Kazanskiy N, Khonina S, Butt M Biosensors (Basel). 2023; 13(10).

PMID: 37887126 PMC: 10605521. DOI: 10.3390/bios13100933.

References
1.
Adams D, Ando Y, Beirao J, Coelho T, Gertz M, Gillmore J . Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020; 268(6):2109-2122. PMC: 8179912. DOI: 10.1007/s00415-019-09688-0. View

2.
Sekijima Y . Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015; 86(9):1036-43. DOI: 10.1136/jnnp-2014-308724. View

3.
Schmidt H, Waddington-Cruz M, Botteman M, Carter J, Chopra A, Hopps M . Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2017; 57(5):829-837. PMC: 5947118. DOI: 10.1002/mus.26034. View

4.
Ando E, Ando Y, Okamura R, Uchino M, Ando M, Negi A . Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Br J Ophthalmol. 1997; 81(4):295-8. PMC: 1722164. DOI: 10.1136/bjo.81.4.295. View

5.
Ando Y, Adams D, Benson M, Berk J, Plante-Bordeneuve V, Coelho T . Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022; 29(3):143-155. DOI: 10.1080/13506129.2022.2052838. View